Axcella Health Inc AXLA:NASDAQ

Last Price$2.12Cboe Real-Time Last Sale as of 3:09PM ET 7/01/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.09(4.43%)
Bid (Size)$2.09 (83)
Ask (Size)$2.15 (100)
Day Low / High$2.02 - 2.14
Volume10.4 K
 

View Biotechnology IndustryPeer Comparison as of 07/01/2022

 

Axcella Health Inc ( NASDAQ )

Price: $2.12
Change: +0.09 (4.43%)
Volume: 10.4 K
3:09PM ET 7/01/2022
 
 

Entasis Therapeutics Holdings Inc ( NASDAQ )

Price: $2.19
Change: -0.005 (0.23%)
Volume: 36.9 K
2:27PM ET 7/01/2022
 
 

Champions Oncology Inc ( NASDAQ )

Price: $8.01
Change: +0.01 (0.12%)
Volume: 230.00
3:58PM ET 6/30/2022
 
 

Enochian Biosciences Inc ( NASDAQ )

Price: $1.91
Change: -0.02 (1.04%)
Volume: 809.8 K
3:12PM ET 7/01/2022
 
 

Leap Therapeutics Inc ( NASDAQ )

Price: $1.17
Change: +0.02 (1.74%)
Volume: 159.9 K
2:59PM ET 7/01/2022
 

Read more news Recent News

Wedbush Cuts Axcella Health's Price Target to $7 From $10 on Termination of AXA1665/OHE Trial; Outperform Rating Kept
6:55AM ET 5/27/2022 MT Newswires

Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $7 to $19, according to analysts polled by Capital IQ. (MT...

Axcella Completes Patient Enrollment for Phase 2a Long COVID-19 Trial
8:33AM ET 5/26/2022 MT Newswires

Axcella (AXLA) said Thursday it has completed the enrollment of 40 patients into a phase 2a trial of AXA1125 as a potential treatment for long COVID-19, a...

--Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept
11:54AM ET 5/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (AXLA) AXCELLA THERAPEUTICS Reports Q1 Loss $-0.46
7:01AM ET 5/05/2022 MT Newswires

...

Company Profile

Business DescriptionAxcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA. View company web site for more details
Address840 Memorial Drive
Cambridge, Massachusetts 02139
Phone+1.857.320.2200
Number of Employees49
Recent SEC Filing06/03/20224
President, Chief Executive Officer & DirectorWilliam R. Hinshaw
Chief Financial Officer & Senior Vice PresidentRobert W. Crane
Chief Scientific Officer, Senior VP-R&DTony Tramontin
Chief Medical Officer & Senior Vice PresidentMargaret Koziel

Company Highlights

Price Open$2.00
Previous Close$2.03
52 Week Range$1.35 - 4.81
Market Capitalization$111.5 M
Shares Outstanding52.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.75
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-202.08%

Analyst Ratings as of 05/06/2022

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset